TG THERAPEUTICS INC (TGTX) Stock Fundamental Analysis

NASDAQ:TGTX • US88322Q1085

29.4 USD
-0.69 (-2.29%)
At close: Mar 2, 2026
29.4 USD
0 (0%)
After Hours: 3/2/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Taking everything into account, TGTX scores 5 out of 10 in our fundamental rating. TGTX was compared to 520 industry peers in the Biotechnology industry. TGTX has only an average score on both its financial health and profitability. TGTX is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make TGTX suitable for growth investing!


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year TGTX was profitable.
  • In the past year TGTX has reported a negative cash flow from operations.
  • In multiple years TGTX reported negative net income over the last 5 years.
  • In the past 5 years TGTX always reported negative operating cash flow.
TGTX Yearly Net Income VS EBIT VS OCF VS FCFTGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

1.2 Ratios

  • TGTX has a better Return On Assets (42.06%) than 99.04% of its industry peers.
  • With an excellent Return On Equity value of 69.01%, TGTX belongs to the best of the industry, outperforming 99.04% of the companies in the same industry.
  • TGTX has a Return On Invested Capital of 12.39%. This is amongst the best in the industry. TGTX outperforms 95.00% of its industry peers.
Industry RankSector Rank
ROA 42.06%
ROE 69.01%
ROIC 12.39%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TGTX Yearly ROA, ROE, ROICTGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

1.3 Margins

  • With an excellent Profit Margin value of 72.56%, TGTX belongs to the best of the industry, outperforming 98.46% of the companies in the same industry.
  • TGTX's Operating Margin of 20.01% is amongst the best of the industry. TGTX outperforms 94.04% of its industry peers.
  • TGTX has a Gross Margin of 83.66%. This is amongst the best in the industry. TGTX outperforms 86.92% of its industry peers.
  • TGTX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 20.01%
PM (TTM) 72.56%
GM 83.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.58%
GM growth 5YN/A
TGTX Yearly Profit, Operating, Gross MarginsTGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TGTX is still creating some value.
  • TGTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TGTX Yearly Shares OutstandingTGTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
TGTX Yearly Total Debt VS Total AssetsTGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • TGTX has an Altman-Z score of 6.86. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
  • TGTX's Altman-Z score of 6.86 is fine compared to the rest of the industry. TGTX outperforms 75.96% of its industry peers.
  • A Debt/Equity ratio of 0.38 indicates that TGTX is not too dependend on debt financing.
  • The Debt to Equity ratio of TGTX (0.38) is worse than 69.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z 6.86
ROIC/WACC1.4
WACC8.85%
TGTX Yearly LT Debt VS Equity VS FCFTGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • TGTX has a Current Ratio of 4.10. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
  • TGTX has a Current ratio of 4.10. This is comparable to the rest of the industry: TGTX outperforms 48.65% of its industry peers.
  • TGTX has a Quick Ratio of 3.29. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of TGTX (3.29) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 3.29
TGTX Yearly Current Assets VS Current LiabilitesTGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • TGTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 257.14%, which is quite impressive.
  • TGTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 87.32%.
  • The Revenue has been growing by 426.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)257.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
Revenue 1Y (TTM)87.32%
Revenue growth 3Y504.86%
Revenue growth 5Y426.73%
Sales Q2Q%78%

3.2 Future

  • The Earnings Per Share is expected to grow by 52.96% on average over the next years. This is a very strong growth
  • TGTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.78% yearly.
EPS Next Y221.55%
EPS Next 2Y115.98%
EPS Next 3Y83.88%
EPS Next 5Y52.96%
Revenue Next Year45.91%
Revenue Next 2Y35.06%
Revenue Next 3Y33.89%
Revenue Next 5Y25.78%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TGTX Yearly Revenue VS EstimatesTGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
TGTX Yearly EPS VS EstimatesTGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 58.80, which means the current valuation is very expensive for TGTX.
  • Compared to the rest of the industry, the Price/Earnings ratio of TGTX indicates a rather cheap valuation: TGTX is cheaper than 89.62% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of TGTX to the average of the S&P500 Index (27.13), we can say TGTX is valued expensively.
  • The Price/Forward Earnings ratio is 18.29, which indicates a rather expensive current valuation of TGTX.
  • 93.85% of the companies in the same industry are more expensive than TGTX, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.11, TGTX is valued a bit cheaper.
Industry RankSector Rank
PE 58.8
Fwd PE 18.29
TGTX Price Earnings VS Forward Price EarningsTGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • TGTX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TGTX is cheaper than 91.54% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 38.38
TGTX Per share dataTGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as TGTX's earnings are expected to grow with 83.88% in the coming years.
PEG (NY)0.27
PEG (5Y)N/A
EPS Next 2Y115.98%
EPS Next 3Y83.88%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TGTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TG THERAPEUTICS INC

NASDAQ:TGTX (3/2/2026, 8:00:00 PM)

After market: 29.4 0 (0%)

29.4

-0.69 (-2.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-04
Inst Owners63.66%
Inst Owner Change1.6%
Ins Owners6.78%
Ins Owner Change-20.54%
Market Cap4.69B
Revenue(TTM)616.29M
Net Income(TTM)447.18M
Analysts78.67
Price Target45.05 (53.23%)
Short Float %19.84%
Short Ratio15.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-44.81%
Min EPS beat(2)-60.92%
Max EPS beat(2)-28.7%
EPS beat(4)0
Avg EPS beat(4)-49.18%
Min EPS beat(4)-83.83%
Max EPS beat(4)-23.26%
EPS beat(8)2
Avg EPS beat(8)-7.43%
EPS beat(12)5
Avg EPS beat(12)38.02%
EPS beat(16)8
Avg EPS beat(16)30.8%
Revenue beat(2)1
Avg Revenue beat(2)1.2%
Min Revenue beat(2)-1.78%
Max Revenue beat(2)4.19%
Revenue beat(4)2
Avg Revenue beat(4)-0.91%
Min Revenue beat(4)-6.11%
Max Revenue beat(4)4.19%
Revenue beat(8)6
Avg Revenue beat(8)3.3%
Revenue beat(12)9
Avg Revenue beat(12)33.32%
Revenue beat(16)10
Avg Revenue beat(16)24.87%
PT rev (1m)-0.91%
PT rev (3m)-0.27%
EPS NQ rev (1m)-1.75%
EPS NQ rev (3m)32.55%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)293.06%
Revenue NQ rev (1m)2.92%
Revenue NQ rev (3m)5.41%
Revenue NY rev (1m)0.91%
Revenue NY rev (3m)4.75%
Valuation
Industry RankSector Rank
PE 58.8
Fwd PE 18.29
P/S 7.62
P/FCF N/A
P/OCF N/A
P/B 7.24
P/tB 7.24
EV/EBITDA 38.38
EPS(TTM)0.5
EY1.7%
EPS(NY)1.61
Fwd EY5.47%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS3.86
BVpS4.06
TBVpS4.06
PEG (NY)0.27
PEG (5Y)N/A
Graham Number6.76
Profitability
Industry RankSector Rank
ROA 42.06%
ROE 69.01%
ROCE 13.56%
ROIC 12.39%
ROICexc 14.68%
ROICexgc 14.68%
OM 20.01%
PM (TTM) 72.56%
GM 83.66%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.58%
GM growth 5YN/A
F-Score5
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Debt/EBITDA 1.99
Cap/Depr 362.71%
Cap/Sales 0.03%
Interest Coverage 5.09
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.1
Quick Ratio 3.29
Altman-Z 6.86
F-Score5
WACC8.85%
ROIC/WACC1.4
Cap/Depr(3y)142.96%
Cap/Depr(5y)115.14%
Cap/Sales(3y)0.02%
Cap/Sales(5y)1.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)257.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
EPS Next Y221.55%
EPS Next 2Y115.98%
EPS Next 3Y83.88%
EPS Next 5Y52.96%
Revenue 1Y (TTM)87.32%
Revenue growth 3Y504.86%
Revenue growth 5Y426.73%
Sales Q2Q%78%
Revenue Next Year45.91%
Revenue Next 2Y35.06%
Revenue Next 3Y33.89%
Revenue Next 5Y25.78%
EBIT growth 1Y194.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year77.12%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.86%
OCF growth 3YN/A
OCF growth 5YN/A

TG THERAPEUTICS INC / TGTX FAQ

What is the fundamental rating for TGTX stock?

ChartMill assigns a fundamental rating of 5 / 10 to TGTX.


What is the valuation status for TGTX stock?

ChartMill assigns a valuation rating of 5 / 10 to TG THERAPEUTICS INC (TGTX). This can be considered as Fairly Valued.


Can you provide the profitability details for TG THERAPEUTICS INC?

TG THERAPEUTICS INC (TGTX) has a profitability rating of 5 / 10.


Can you provide the financial health for TGTX stock?

The financial health rating of TG THERAPEUTICS INC (TGTX) is 5 / 10.


What is the earnings growth outlook for TG THERAPEUTICS INC?

The Earnings per Share (EPS) of TG THERAPEUTICS INC (TGTX) is expected to grow by 221.55% in the next year.